Lipella Pharmaceuticals to Acquire Bio-Gen Innovations for $1M

TL;DR

Lipella buying Bio-Gen for $1M, closing Q3.

AI Summary

Lipella Pharmaceuticals Inc. announced on August 6, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Bio-Gen Innovations, Inc. for an aggregate purchase price of $1,000,000. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition could expand Lipella's product pipeline and market reach in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and the possibility that the acquired company may not perform as expected.

Key Numbers

• $1.0M — Acquisition Price (Aggregate purchase price for Bio-Gen Innovations, Inc.)

Key Players & Entities

• Lipella Pharmaceuticals Inc. (company) — Registrant
• Bio-Gen Innovations, Inc. (company) — Target company for acquisition
• $1,000,000 (dollar_amount) — Aggregate purchase price for the acquisition
• August 6, 2024 (date) — Date of the definitive agreement
• third quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar

Filing Documents

• g084375_8k.htm (8-K) — 35KB
• 0001753926-24-001361.txt ( ) — 206KB
• lipo-20240806.xsd (EX-101.SCH) — 3KB
• lipo-20240806_lab.xml (EX-101.LAB) — 33KB
• lipo-20240806_pre.xml (EX-101.PRE) — 22KB
• g084375_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events Lipella Pharmaceuticals Inc. (the "Company") intends to hold its 2024 annual meeting of stockholders (the "2024 Annual Meeting") on September 10, 2024. The Company has set the close of business on August 1, 2024 as the record date for the determination of stockholders who are entitled to notice of, and to vote at, the 2024 Annual Meeting and any adjournments thereof. The time and location of the 2024 Annual Meeting will be specified in the Company's definitive proxy statement on Schedule 14A for the 2024 Annual Meeting. The Company's 2023 annual meeting of stockholders (the "2023 Annual Meeting") was held on November 21, 2023. As the date of the 2024 Annual Meeting will have been changed by more than 30 days from the one-year anniversary of the 2023 Annual Meeting, the Company is informing stockholders of this change in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is informing stockholders of the new dates described below for submitting stockholder proposals and other matters. Pursuant to Rule 14a-8 of the Exchange Act, a stockholder intending to present a proposal to be included in the proxy statement for the 2024 Annual Meeting must deliver the proposal in writing to the Company's Secretary at its corporate office at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208 no later than a reasonable time before we begin to print and mail the proxy materials for the 2024 Annual Meeting. To be considered for inclusion in this year's proxy materials for the 2024 Annual Meeting, shareholder proposals must be submitted in writing on or before the close of business on August 8, 2024, which the Company believes to be a reasonable deadline under the applicable rules of the Exchange Act. In addition to complying with such deadline, stockholder proposals intended to be considered for inclusion in the Company's proxy materials for the 2024 Annual Meeting must also comply with Delaware

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 6, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR